FDA Approves Brentuximab Vedotin for Frontline CD30+ PTCL
The FDA has approved brentuximab vedotin for use in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma.
Source: OncLive
The FDA has approved brentuximab vedotin for use in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma.
Source: OncLive
Your Technology Source, Your Technology Team
Server Maintenance, Web Development, Mobile Application Solutions, SEO Services and more
Contact Us: contact@crwetech.com
Our content delivery solution through CRWE WORLD, CRWE Press Release and CRWE Tube gives corporations and businesses a vehicle to expand their exposure
CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform
Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!
Contact Us: contact@crweworld.com